000087840 001__ 87840
000087840 005__ 20231023123341.0
000087840 0248_ $$2sideral$$a116225
000087840 037__ $$aART-2019-116225
000087840 041__ $$aeng
000087840 100__ $$0(orcid)0000-0001-9962-3387$$aFrutos Pérez-Surio, Alberto$$uUniversidad de Zaragoza
000087840 245__ $$aDrug-drug interactions between tyrosine kinase inhibitors and concomitant medications: drug safety in chronic myeloid leukemia treatment.
000087840 260__ $$c2019
000087840 5060_ $$aAccess copy available to the general public$$fUnrestricted
000087840 5203_ $$aBackground: Clinical Pharmacist should be aware of hematologic toxicities from tyrosine kinase inhibitors (TKI) used to treat chronic myelogenous leukemia (CML). Drug-drug interactions (DDI) may be problematic.
Objective: To analyze DDI between TKI and the concomitant medication.
Setting: Retrospective observational study carried in a tertiary hospital of Spain.
Method: A bibliographic search was made on the UpToDate®, Lexicomp® and Micromedex® software platforms to search for evidence on DDI between TKI and the concomitant medication.
Main outcome measure: Number of interactions with respect to sex,to number of concomitant drugs, and to TKI used.
Results: A total of 28 patients were analyzed. 78.6% of patients had medication associated with the TKI. There was a total of 50 significant DDI, out of a total of 128 drugs, so the risk of having interaction in the study population was 39.1%. Regarding the management of the interactions by the hematologist and the acceptance of the pharmaceutical intervention: 10 patients experienced 14 high-level interactions. Of these the doctor knew 50% and had performed intervention in all cases: modify the treatment in 28.6%, consulted with service responsible for treatment in 42.8% and spaced the intake of drugs in 28.6%. It is important to periodically review concomitant medication and to have a strategy to manage interactions. The role of the clinical pharmacist is essential in communication with the patient, assessment of treatments, detecting potential interactions and disseminating information among the multidisciplinary team.
Conclusion: All patients who are prescribed oral antineoplastic drugs are provided patient education materials about TKI, which include possible interactions. Any changes in the patient’s medications prompt a review for DDI.
000087840 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
000087840 592__ $$a0.101$$b2019
000087840 593__ $$aPharmacology$$c2019$$dQ4
000087840 593__ $$aPharmaceutical Science$$c2019$$dQ4
000087840 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000087840 700__ $$aLozano Ortiz, Roberto
000087840 700__ $$aMartinez Crespo, Alejandro
000087840 7102_ $$11008$$2615$$aUniversidad de Zaragoza$$bDpto. Microb.Med.Pr.,Sal.Públ.$$cÁrea Medic.Prevent.Salud Públ.
000087840 773__ $$g31, 4 (2019), 192-200$$tPharmakeftiki$$x1105-4999
000087840 85641 $$uhttps://www.hsmc.gr/en/pharmakeftiki-journal/$$zTexto completo de la revista
000087840 8564_ $$s257546$$uhttps://zaguan.unizar.es/record/87840/files/texto_completo.pdf$$yVersión publicada
000087840 8564_ $$s415848$$uhttps://zaguan.unizar.es/record/87840/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000087840 909CO $$ooai:zaguan.unizar.es:87840$$particulos$$pdriver
000087840 951__ $$a2023-10-23-12:20:46
000087840 980__ $$aARTICLE